Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:11:55.642Z.
Calculation as of: 2026-10-06T16:11:55.642Z.
Quote observation: 2026-10-06T16:10:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869772d5b15fe2f366f7470de3318cdd420f1d22994776f46b79eb6f67ec6a89
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Eupraxia Pharmaceuticals Inc.
Market Cap
$267.51M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.87M
EV/EBIT Ratio
N/A
TTM Avg
11.31x
3Y Avg
11.31x
5Y Avg
15.93x
Market Cap
$268.17M
EV/EBIT Ratio
N/A
TTM Avg
5.32x
3Y Avg
26.78x
5Y Avg
44.78x
Market Cap
$266.71M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.87M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.22M
EV/EBIT Ratio
N/A
TTM Avg
162862.62x
3Y Avg
112489.16x
5Y Avg
112489.16x
Market Cap
$274.62M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$277.05M
EV/EBIT Ratio
N/A
TTM Avg
102.60x
3Y Avg
102.60x
5Y Avg
102.60x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $267.51M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.87M | N/A | 11.31x | 11.31x | 15.93x |
| OraSure Technologies, Inc. (OSUR)vs › | $268.17M | N/A | 5.32x | 26.78x | 44.78x |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.71M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $261.87M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $261.22M | N/A | 162862.62x | 112489.16x | 112489.16x |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $274.77M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.05M | N/A | 102.60x | 102.60x | 102.60x |
| Fate Therapeutics, Inc. (FATE)vs › | $277.46M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
